Looks like you’re on the UK site. Choose another location to see content specific to your location

AbbVie and Simcere Join Forces for Multiple Myeloma Breakthrough
AbbVie and Simcere Zaiming have embarked on a strategic partnership exceeding $1 billion to accelerate the development of SIM0500, a novel trispecific antibody currently in phase 1 trials for multiple myeloma, a challenging and incurable blood cancer. The agreement reflects both companies’ dedication to tackling significant unmet medical needs in oncology.
Multiple myeloma affects around 24,000 people in the UK and represents a significant portion of blood-related cancers. Despite existing treatments, current therapies often fall short, leaving room for innovative solutions. SIM0500, developed with Simcere’s T-cell engager polyspecific antibody technology, targets GPRC5D, BCMA, and CD3, boasting strong anti-tumour activity by harnessing robust T-cell cytotoxicity.
Under the terms, AbbVie secures licencing options and marketing rights in specified regions while also committing to a substantial financial package for Simcere, including an upfront payment and success-based milestones. Simcere’s receipt for tiered royalties outside Greater China further underscores the partnership’s strategic intent. This collaboration not only emphasises AbbVie’s expansive focus in haematology but also marks Simcere’s entrance onto a broader global stage.
With this promising collaboration, AbbVie and Simcere aim to transform the treatment landscape for multiple myeloma. This partnership underscores the industry’s ongoing commitment to innovation and patient care in oncology, aiming to bring hope to those affected by this challenging disease.
For the latest updates and in-depth insights into the world of Pharmaceuticals, including breakthrough treatments, industry trends, and regulatory news, contact Marcus Chalk today!
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard